SEARCH

    Saved articles

    You have not yet added any article to your bookmarks!

    Browse articles
    Select News Languages

    GDPR Compliance

    We use cookies to ensure you get the best experience on our website. By continuing to use our site, you accept our use of cookies, Privacy Policies, and Terms of Service.

    Kenvue stock rebounds: Tylenol maker rises 6% after Donald Trump’s autism claims; analysts see limited legal impact

    4 hours ago

    Kenvue shares rebounded after a sharp fall triggered by Donald Trump's unfounded claims linking Tylenol to autism. Trump advised pregnant women to avoid the drug, despite a lack of new scientific evidence. Kenvue refuted the claims, while an analyst predicted limited lawsuit risks but cautioned about potential consumption decline due to negative publicity.
    Click here to Read more
    Prev Article
    IATA study finds sufficient sustainable aviation fuel feedstock exists to achieve net zero emissions by 2050
    Next Article
    Rupee at all-time low! Currency slumps 45 paise to close at 88.73 against US dollar; Visa fee shock, FII outflows add pressure

    Related Business Updates:

    Comments (0)

      Leave a Comment